Page 30 - Demo

24DIRECTORYOFSINGAPOREPROCESS&CHEMICALSINDUSTRIES2023/2024toboostbiologicsmanufacturingincludingrecombinanttherapeuticproteinsandvaccinesmakingitbest-in-classwell-positionedfortheintroductionofnewproductsandnovelmanufacturingtechnologiesInapressreleaseMrLimKengHuiAssistantChiefExecutiveofA*STARScienceandEngineeringResearchCouncilnotedNewopportunitieswillemergeasthebiomanufacturingindustryundergoesmajorchangesbroughtaboutbytherapidpaceofdigitalisationIndustry40andtheneedforgreatersustainabilityAsSingaporemakesbiopharmaproductionapriorityareainitsResearchInnovationandEnterprise2025PlanA*STARaimstocontributeourR&DcapabilitiesthroughBioPIPStohelpmakethelocalbiomanufacturingindustrybecomemoreagileandbetterpositionedtobenefitfromnewproductsandtechnologiesSpecificallyBioPIPSwillhavethreeworkstreams•TheSensingandModellingworkstreamaimstoharnessmachinelearningandmechanisticmodellingtechnologiestogetherwithsmartsensorstoenablesimplifiedandfasterworkflowsDataanalyticswillenabletheeffectivetranslationofprocessknowledgegainedintoperformanceimprovementswhichinturnbenefitstheoverallmanufacturingprocess•TheSustainabilityworkstreamfocusesontacklingsustainabilitychallengesinbiologicsandvaccinesmanufacturingwhichtypicallyutilisessingle-use(disposable)equipmentduetotheextremelysterileenvironmentneededforproductpurityThisworkstreamwillexploretheuseofnovelmaterialsandcirculareconomyapproachestoaddressthischallengeaswellasmodelstopromotemoresustainableandresilientsupplychains•TheCompliantAgilityworkstreamfocusesontheremovalofmanualtaskstoachievegreaterproductivityinthemanufacturingfacilitieswhilemaintainingcompliancestatusbyusingsolutionslikeroboticsandadvancedanalyticsBioPIPSisinlinewithSingaporesManufacturing2030visionwhichaimstoanchorleadingmanufacturingactivitiestogrowthecountrysmanufacturingvalue-addby50%from2020ThesolutionsdevelopedthroughBioPIPSwillenhanceSingaporescapabilitiestomeetthegrowingglobaldemandforbiologicsandvaccinesaswellasequippharmaceuticalcompaniesherewiththeresourcestoscaleupandrespondmorerapidlytofuturepandemicsBycollaboratingtotacklecommonchallengeswecanleveragediverseskillsandcapabilitiestocreateasustainablemanufacturingenvironmentinSingaporeWealsolookforwardtodevelopingnewwaystomonitor and control ourprocesses and automateourmanufacturingoperationssaidChanSiongWanSiteDirectorGSKGSKopenedaproductionfacilityinJuronginNovember2022toproduceacytotoxiccomponentforantibody-drugconjugatestotreatcancerSanofibeganconstructiononitsS$434millionfirst-of-its-kindfullydigitalisedandmodularvaccineproductionplantinSingaporein April TheEVolutiveFacilitywillbringadvanceddigitalandmodularvaccineproductioncapabilitiestotheAsiaregionTheBioPIPSprogrammesfocusontransformingbiologicsandvaccinesmanufacturingthroughpre-competitivepartnershipsisalignedwithSanofisvisionfortheEVolutiveFacilitytocontinuouslypushtheenvelopeofinnovationforbiopharmaceuticalmanufacturingsaidMrKohLiangHongSiteHeadEVolutiveFacilitySanofiAs for Takedait sees the objectives ofBioPIPSasbeingalignedtoitsambitionsofbeingnetcarbon zeroin our operationsby2035WelookforwardtothispartnershipwithSingaporesresearchecosystemtofurtherstrengthenourcapabilitiesanddiscovernewandsustainablewaystodevelopandmanufactureinnovativemedicinetodeliveronTakedascommitmenttoPatientPeopleandPlanetsaidGeorgeLamSiteHeadTakedaManufacturingSingaporeBioPIPSbuildsontheconsortiummodelestablishedbythePharmaInnovationProgrammeSingaporewhichwassetuptoboostSingaporescapabilities formanufacturingofsmallmoleculedrugsmadeofchemicalcompounds